Throughout the past few weeks, the world has faced an unprecedented heartbreaking global drama that affected and will continue to affect almost all areas of economics. Unfortunately, the clinical research sector is no exception, and, given its global outreach, it is unavoidable that almost all companies will have to face challenges.

Ukraine and Russia, with the joint population of over 190 million people, have always been top-recruiters in all global clinical trials and have been notorious for rescuing numerous trials for our Sponsors who faced recruitment challenges and delays in other countries. Therefore, having crossed out these two countries from the clinical research landscape will inevitably bring losses to the global pharmaceutical and biotechnological R&D sector. It is a grievous loss for Accell as well, and with a heavy heart do we announce that temporarily we are forced to cease our new activities in Russia and Ukraine. All previously taken responsibilities will be carried out to the best of our capabilities. In the meantime, we do our best to take care and provide support to all our employees in both Ukrainian and Russian offices and hope that the conflict will be over soon.

However, Accell Clinical LLC continues its operations across Eastern Europe and CIS countries and offers its clinical research services in such countries as: Bulgaria, Croatia, Estonia, Georgia, Hungary, Kazakhstan, Latvia, Lithuania, Montenegro, Poland, Romania, and Serbia. You can always reach out to us at bd@accellclinical.com to discuss your clinical trial needs.